Faster global financial news!
AstraZeneca
-
AstraZeneca PLC(AZN) Q3: EPS 2.79 USD (above forecast)
AstraZeneca PLC(AZN) Q3 EPS: 2.79 USD; Forecast 2.6 USD Reporting period: 2026 Q3 (period ended 2026-09-30) Release date: 2026-10-30
-
AstraZeneca: Hong Kong Needs New Funding Models to Attract Global Pharmaceutical Investment
The Cambridge-based multinational pharmaceutical giant stated that if Hong Kong can establish a new healthcare financing model, it will attract more global biotech investment. AstraZeneca has invested
-
Summit Therapeutics shares rose after AstraZeneca Plc announced a $2 billion strategic equity investment in the cancer drugmaker to jointly develop drugs.
Summit Therapeutics shares rose after AstraZeneca Plc announced a $2 billion strategic equity investment in the cancer drugmaker to jointly develop drugs.
-
Alnylam Pharmaceuticals' stock price has fallen by approximately 40% this year, but Wall Street analysts generally remain optimistic, with an average target price indicating about 50% upside potential.
Shares of biotechnology company Alnylam Pharmaceuticals (Nasdaq: ALNY) have fallen by approximately 40% year-to-date, but Wall Street analysts remain largely optimistic about its prospects. According
-
China's Akeso Says Its Cancer Drug Ivonescimab Outperformed AstraZeneca's Imfinzi in Phase 3 Trial for Biliary Tract Cancer
Chinese biopharmaceutical firm Akeso announced on Wednesday that its immunotherapy drug ivonescimab had outperformed AstraZeneca’s Imfinzi in a head-to-head phase-three trial for biliary tract cancer.
-
AstraZeneca acquires global rights to lung cancer treatment Zegfrovy from Dizal Pharmaceutical for $600 million upfront, with potential for up to $1.5 billion
AstraZeneca will pay Dizal Pharmaceutical Co., Ltd. an initial $600 million, with an additional $900 million contingent on development, regulatory, and sales milestones. Zegfrovy (sunvozertinib) is an
-
A Wall Street Journal commentary noted that AstraZeneca shares are good value, whether a deal happens or not.
The Wall Street Journal commented that while the logic behind pharmaceutical giants' mergers and acquisitions is debatable, AstraZeneca's own performance record is not, considering its stock a bargain
-
AstraZeneca and Bristol-Myers Squibb are in merger talks; if the deal goes through, it would create a pharmaceutical giant with a market capitalization of nearly $400 billion.
According to the British *Financial Times*, British pharmaceutical giant AstraZeneca and U.S. pharmaceutical company Bristol-Myers Squibb are engaged in advanced merger talks. If the deal is finalized
-
AstraZeneca PLC(AZN) Q3: EPS 2.79 USD (above forecast)
AstraZeneca PLC(AZN) Q3 EPS: 2.79 USD; Forecast 2.6 USD Reporting period: 2026 Q3 (period ended 2026-09-30) Release date: 2026-10-30
-
AstraZeneca: Hong Kong Needs New Funding Models to Attract Global Pharmaceutical Investment
The Cambridge-based multinational pharmaceutical giant stated that if Hong Kong can establish a new healthcare financing model, it will attract more global biotech investment. AstraZeneca has invested
-
Summit Therapeutics shares rose after AstraZeneca Plc announced a $2 billion strategic equity investment in the cancer drugmaker to jointly develop drugs.
Summit Therapeutics shares rose after AstraZeneca Plc announced a $2 billion strategic equity investment in the cancer drugmaker to jointly develop drugs.
-
Alnylam Pharmaceuticals' stock price has fallen by approximately 40% this year, but Wall Street analysts generally remain optimistic, with an average target price indicating about 50% upside potential.
Shares of biotechnology company Alnylam Pharmaceuticals (Nasdaq: ALNY) have fallen by approximately 40% year-to-date, but Wall Street analysts remain largely optimistic about its prospects. According
-
China's Akeso Says Its Cancer Drug Ivonescimab Outperformed AstraZeneca's Imfinzi in Phase 3 Trial for Biliary Tract Cancer
Chinese biopharmaceutical firm Akeso announced on Wednesday that its immunotherapy drug ivonescimab had outperformed AstraZeneca’s Imfinzi in a head-to-head phase-three trial for biliary tract cancer.
-
AstraZeneca acquires global rights to lung cancer treatment Zegfrovy from Dizal Pharmaceutical for $600 million upfront, with potential for up to $1.5 billion
AstraZeneca will pay Dizal Pharmaceutical Co., Ltd. an initial $600 million, with an additional $900 million contingent on development, regulatory, and sales milestones. Zegfrovy (sunvozertinib) is an
-
A Wall Street Journal commentary noted that AstraZeneca shares are good value, whether a deal happens or not.
The Wall Street Journal commented that while the logic behind pharmaceutical giants' mergers and acquisitions is debatable, AstraZeneca's own performance record is not, considering its stock a bargain
-
AstraZeneca and Bristol-Myers Squibb are in merger talks; if the deal goes through, it would create a pharmaceutical giant with a market capitalization of nearly $400 billion.
According to the British *Financial Times*, British pharmaceutical giant AstraZeneca and U.S. pharmaceutical company Bristol-Myers Squibb are engaged in advanced merger talks. If the deal is finalized
- No data
AstraZeneca
24H Trending
-
1
Bitcoin Price Breaks $77,000: Multiple Factors Drive Current Rally
-
2
Al Jazeera: Israeli attacks on Gaza kill at least 4 Palestinians, UN Human Rights Office warns of ethnic cleansing risk
-
3
US banks are owed $349B by private credit funds, as PIK interest payments rise to 10% of loans
-
4
Musk retweeted that as of October 31, the number of Starlink satellites has reached 11,184, accounting for 66% of the total active satellites globally.
-
5
Bitcoin staking protocol b14g says $97 million CORE drained, pauses contracts
-
6
Nikkei Asia: Overseas entities' JPY bond issuance reaches a record $16 billion as the AI funding race spreads to Japan
-
7
Al Jazeera: Palestinian Man Succumbs to Injuries After Israeli Drone Strike in Gaza
-
8
SpaceXAI, the AI division of SpaceX, failed to dismiss an air pollution lawsuit filed by the NAACP, with the judge ruling that the case will proceed.
-
9
Binance confirmed that it has transferred 7,499 Bitcoins to the SAFU fund, stating that it has recovered 90% of the stolen assets and pledged to rebuild the emergency fund to approximately $1 billion.
-
10
Chainalysis: Ethereum Reorg Causes THORChain Emergency Pause, Accidentally Delays Binance Hacked Funds Laundering
Markets Today
Recommended Reading
Hot Topics
Svmuu focuses on blockchain industry trends and cutting-edge cryptocurrency news, while also covering real-time market data and in-depth analysis of the Hong Kong, U.S., and foreign exchange markets. Here, you can not only access professional 24/7 news updates and accurate market data, but also utilize practical investment tools to help you capitalize on opportunities in both digital assets and traditional financial markets. Whether you are a blockchain enthusiast or an investor in Hong Kong, U.S., or foreign exchange markets, we provide efficient and timely information services to empower your investment decisions.
- User Agreement
- Privacy Policy
- Contact Us
- Business Partnerships
- Disclaimer
- Content Statement
- About Us
- Sitemap
Coming Soon!
